Heart Failure

This heart failure channel offers news and new technology to treat heart failure. This includes for new innovations to treat congestive heart failure (CHF). The channel includes news on HFpEF and HFrEF. Heart failure occurs when the heart is no longer able to pump as much blood as the body requires. This can lead to enlargement of the heart because the muscle works harder to supply blood, but the pumping is ineffective. This may be due to defects in the myocardium, such as an infarct, or due to structural issues such as severe valve regurgitation. The disease is divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant  or a left ventricular assist device (LVAD).

FDA Grants Fast Track Designation for Farxiga in Heart Failure
News | Heart Failure | September 18, 2019
September 18, 2019 — AstraZeneca announced the U.S. Food and Drug Administration (FDA) has granted Fast Track...
Corvia Medical and physIQ Partner in Global Phase 3 Heart Failure Device Clinical Trial

The REDUCE LAP HF-II study will combine Corvia Medical's InterAtrial Shunt Device (IASD), pictured here, with physIQ's continuous monitoring platform to evaluate the device's efficacy in patients with heart failure. Image courtesy of Corvia Medical.

News | Heart Failure | September 12, 2019
September 12, 2019 — Corvia Medical has sponsored and is actively enrolling patients in a heart failure (HF) device...
Reducing Secondary Mitral Regurgitation in Heart Failure Does Not Improve Two-year Outcomes
News | Heart Valve Technology | September 11, 2019
September 11, 2019 — Percutaneous reduction of secondary mitral regurgitation in patients with heart failure does not...
 Tiny Wearable Cameras May Improve Quality of Life in Heart Failure Patients

Image courtesy of Amazon.com

News | Heart Failure | September 11, 2019
September 11, 2019 — The ever-present devices that seem to track all our moves can be annoying, intrusive or worse, but...
PARAGON-HF Misses Endpoint in Preserved Heart Failure
News | Heart Failure | September 11, 2019
September 11, 2019 — The angiotensin neprilysin inhibitor sacubitril/valsartan (Entresto) missed its primary endpoint...
Farxiga Significantly Reduces Cardiovascular Death and Worsening of Heart Failure
News | Heart Failure | September 09, 2019
September 9, 2019 — AstraZeneca announced detailed results from the landmark Phase III DAPA-HF trial that showed...
ASNC Announces Multisocietal Cardiac Amyloidosis Imaging Consensus
News | Cardiac Imaging | September 09, 2019
September 9, 2019 — The American Society of Nuclear Cardiology (ASNC) published a new expert consensus document along...
Dapagliflozin, Forxiga, was found to help improve outcomes in heart failure patients with reduced ejection fraction (HFrEF) at ESC 2019. #ESC19 #ESC2019
News | Heart Failure | September 09, 2019
September 9, 2019 — The drug Dapagliflozin was found to reduce death and hospitalization in patients who have heart...
Entresto Improved Measures of Heart Structure and Function in Heart Failure Patients
News | Heart Failure | September 04, 2019
September 4, 2019 – Novartis announced results from two new clinical trials evaluating improvement in heart structure...
Renovacor Closes $11 Million Series A Financing for New Cardiovascular Gene Therapy
News | Stem Cell Therapies | August 22, 2019
August 22, 2019 — Renovacor Inc, a preclinical-stage biopharmaceutical company, announced the successful completion of...
Insomnia Tied to Higher Risk of Heart Disease and Stroke

Image courtesy of the American Heart Association

News | Cardiac Diagnostics | August 19, 2019
August 19, 2019 — People suffering from insomnia may have an increased risk of coronary artery disease, heart failure...
FDA Approves Barostim Neo System for Advanced Heart Failure Patients. Similar to a pacemaker, the Barostim Neo System uses a pulse generator implanted below the collar bone with a lead that attaches to the carotid artery in the neck. It delivers electrical impulses to baroreceptors in the neck, which sense how blood is flowing through the carotid arteries and relays information to the brain. The brain, in turn, sends signals to the heart and blood vessels that relax the blood vessels.

Similar to a pacemaker, the Barostim Neo System uses a pulse generator implanted below the collar bone with a lead that attaches to the carotid artery in the neck. It delivers electrical impulses to baroreceptors in the neck, which sense how blood is flowing through the carotid arteries and relays information to the brain. The brain, in turn, sends signals to the heart and blood vessels that relax the blood vessels and inhibit the production of stress-related hormones to reduce heart failure symptoms.

Technology | Heart Failure | August 19, 2019
August 19, 2019 — The U.S. Food and Drug Administration (FDA) granted market clearance the Barostim Neo System for the...
Ancora Heart Enrolls First Patient in European Multi-center Study of AccuCinch Heart Failure Therapy
News | Heart Failure | August 14, 2019
August 14, 2019 — Ancora Heart Inc. announced the first patient was enrolled in the CorCinch EU study, a European multi...
Contrast Use in First Transthoracic Echocardiogram for Heart Failure Reduces Repeat Testing
News | Cardiovascular Ultrasound | August 07, 2019
August 7, 2019 — Heart failure is the fourth most common cause for all admission to U.S. hospitals, and it is the most...
Procyrion Receives FDA Breakthrough Device Designation for Aortix System
Technology | Heart Failure | July 30, 2019
July 30, 2019 – Procyrion Inc. secured Breakthrough Device designation by the U.S. Food and Drug Administration (FDA)...